Alain Herrera
Director/Board Member chez NANOBIOTIX
Profil
Alain Herrera is the founder of Onward Therapeutics SA, which was founded in 2019.
He is currently working as an Independent Director at Isofol Medical AB, a Non-Executive Director at International Drug Development Institute SA, a Director at Gustave Roussy Foundation, a Director at PDC Line Pharma SASU, a Director at Fondation A.R.CA.D., a Managing Director at Alain Oncologie Consulting, a Managing Director at Ad Bio Consulting, a Director at Gustave Roussy Transfert, a Non-Executive Director at EMERCell SAS, a Director at ErVimmune SA since 2021, and a Member-Supervisory Board at Nanobiotix SA since 2011.
He also holds the position of MD & Head-Corporate Development at Pharmaengine Europe SARL.
In his former positions, Dr. Herrera served as the Chairman-Europe Region at Chiron Therapeutics, Inc., the Managing Director-Oncology Laboratories at Pierre Fabre SA, and the VP-Global Oncology Business Strategy & Development at Sanofi from 2007 to 2008.
He also held the position of Head-Oncology Platform at Rhône Poulenc Pharma, Inc.
Postes actifs de Alain Herrera
| Sociétés | Poste | Début |
|---|---|---|
| NANOBIOTIX | Director/Board Member | 23/06/2011 |
| ISOFOL MEDICAL AB | Director/Board Member | 04/01/2024 |
Ad Bio Consulting
 Ad Bio Consulting Miscellaneous Commercial ServicesCommercial Services Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Chief Executive Officer | - |
Onward Therapeutics SA
 Onward Therapeutics SA BiotechnologyHealth Technology Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston. | Founder | 01/11/2019 |
EMERCell SAS
 EMERCell SAS Pharmaceuticals: MajorHealth Technology EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed. | Director/Board Member | - |
Gustave Roussy Transfert
 Gustave Roussy Transfert Miscellaneous Commercial ServicesCommercial Services Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care. | Director/Board Member | - |
Pharmaengine Europe SARL
 Pharmaengine Europe SARL Pharmaceuticals: MajorHealth Technology Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Chief Executive Officer | - |
Gustave Roussy Foundation
 Gustave Roussy Foundation Hospital/Nursing ManagementHealth Services Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life. | Director/Board Member | - |
Alain Oncologie Consulting
 Alain Oncologie Consulting Miscellaneous Commercial ServicesCommercial Services Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Chief Executive Officer | - |
| ░░░ ░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Alain Herrera
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SANOFI | Health Technology |
| NANOBIOTIX | Health Technology |
| ISOFOL MEDICAL AB | Health Technology |
| Entreprise privées | 13 |
|---|---|
Pierre Fabre SA
 Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Health Technology |
| Rhône Poulenc Pharma, Inc. | |
| Chiron Therapeutics, Inc. | |
International Drug Development Institute SA
 International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
Gustave Roussy Foundation
Gustave Roussy Foundation Hospital/Nursing ManagementHealth Services Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life. | Health Services |
PDC Line Pharma SASU
 PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | Health Technology |
| Fondation A.R.CA.D. | Miscellaneous |
Alain Oncologie Consulting
Alain Oncologie Consulting Miscellaneous Commercial ServicesCommercial Services Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Commercial Services |
Ad Bio Consulting
Ad Bio Consulting Miscellaneous Commercial ServicesCommercial Services Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Commercial Services |
Pharmaengine Europe SARL
Pharmaengine Europe SARL Pharmaceuticals: MajorHealth Technology Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The private company is based in Paris, France. The CEO of the French company is Alain Herrera. | Health Technology |
Gustave Roussy Transfert
Gustave Roussy Transfert Miscellaneous Commercial ServicesCommercial Services Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care. | Commercial Services |
EMERCell SAS
EMERCell SAS Pharmaceuticals: MajorHealth Technology EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed. | Health Technology |
Onward Therapeutics SA
Onward Therapeutics SA BiotechnologyHealth Technology Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston. | Health Technology |
